Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Warnings-22)

In this article we will discuss Durvalumab (Warnings-22)

In this article, we will discuss Durvalumab (Warnings-22). So, let’s get started.

Hypothyroidism: Immune-mediated hypothyroidism occurred in 8.3% (156/1889) of patients receiving Durvalumab, including Grade 3 (<0.1%) adverse reactions. Events resolved in 31 of the 156 patients and did not lead to permanent discontinuation of IMFINZI in any patients. Systemic corticosteroids were required in 11 patients (11/156) and the majority of patients (152/156) required long-term thyroid hormone replacement.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.